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predictive value of 52% (95%CI, 37%-68%) and a negative predictive value of 97% 
(95%CI, 83%-100%). Results at 6-months follow-up were similar. Total mean medi-
cal costs per patient for PWU and CWU were € 11,302 and € 11,784 (6-months), and 
€ 12,670 and € 13,776 (12-months), respectively. The incremental costs were in favor of 
the PWU patients (€ 482 (6-months), € 1,105 (12-months)). Sensitivity analyses showed 
that the most influential parameters were hospitalization, treatment-related oper-
ations and cost of PET. ConClusions: The introduction of 18F-FDG PET in the 
diagnostic trajectory of laryngeal cancer patients with suspected recurrence after 
radiotherapy is feasible, safe and favorable from clinical and economic perspectives.
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objeCtives: Percutaneous Coronary Intervention (PCI) reduces the morbidity and 
mortality associated with Coronary Artery Disease. However up to a third of patients 
experience cardiac complications, in the year after PCI. Unplanned and emergency 
admissions are costly to the health service. This study aimed to use real-world 
administrative data to explore the costs of post-PCI complications to secondary care 
providers in England. Methods: Patients who received PCI in England between 
March and December 2011 were identified from Hospital Episode Statistic (HES) data. 
Treatment costs to secondary care were estimated using Payment by Results coding 
in the HES data set. All cause and cardiac complication related bootstrapped mean 
health-care costs were estimated at 12months, 24 months and 36 months post-PCI. 
Costs were in pound for cost year 2014. Bootstrapped t-tests were applied to com-
pare costs between those with post-PCI angina and those without. Results: 32492 
met study inclusion criteria (mean age 64 years [SD 11.8], 74% male). Bootstrapped 
cumulative mean costs to the secondary care provider were significantly higher at 
12 months in those with angina at £ 10,215, 95% CI [£10,083, £10,348] vs. £6,552, 95% 
CI [£6,503, £6,601] for those without. Significant cost differences continued to 36 
months post-PCI. These were £14,754 95% CI [£14,571, £14,936] for those with angina 
vs. £8,407, 95% CI [£8,324, £8,489] for those without. At 36 months, cardiac related 
costs, inpatient, outpatient and accident and emergency costs were significantly 
higher in those with angina (P< 0.001). ConClusions: This real-world study dem-
onstrated that patients with cardiac complications post-PCI consumed significantly 
greater secondary care resources than those without, in all cost categories and, 
across all services considered. Decision makers, and clinicians, should be aware 
that interventions and therapeutic strategies associated with lower incidence of 
cardiovascular complications could significantly reduce unplanned admissions and 
associated financial burden to the NHS.
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objeCtives: The Sanger sequencing method has been considered the gold standard 
DNA sequencing technique for approximately 30 years; however, it is now chal-
lenged by next generation sequencing (NGS). The aim of this study was to assess 
the cost entailed by Sanger DNA sequencing when it is used for somatic genet-
ics. Methods: The cost assessment was based on a multicenter study using a 
micro-costing approach. We observed Sanger sequencing sessions that started with 
the DNA sample and finished with the bio-informatics evaluation. The hospitals’ 
point of view was retained. Only direct costs were taken into account. Uncertainty 
was captured for each stage using a deterministic sensitivity analysis. All costs are 
expressed in Euros 2015. Results: Five sequencing sessions were investigated in 
four French cancer centers from February 2015 to May 2015. In total, DNA samples 
from 87 patients with 658 exons were sequenced with a mean duration of 1.815 
minutes per session. The mean total cost of sequencing was € 1,891 (SD: 1,460). 
The cost per patient was € 108 (SD: 30.36) and cost per exon was € 18 (SD: 5.52). The 
personnel (52% of total costs, SD: 0.03) and consumable (43% of total costs, SD: 0.03) 
costs represented the highest cost drivers. The bio-informatics analysis and DNA 
extraction were the costliest stages of the sequencing process (28 and 26%, respec-
tively). Total costs were highly correlated with the number of patients and exons. 
The marginal costs were € 112 and € 12 per additional patient and exon, respec-
tively. ConClusions: Our findings demonstrate the moderate costs of Sanger 
sequencing. These results can be used for further economic analyses comparing 
Sanger sequencing methods with other DNA sequencing methods such as NGS.
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objeCtives: Recent advances in novel diagnostics have led to some concerns 
on the part of purchasers as to whether the diagnostics add value or simply add 
cost. In this study we explore these concerns, using as an example the case of 
antibiotic stewardship protocols based on procalcitonin levels. The objective is to 
assess the economic impact of adopting procalcitonin testing among patients with 
suspected acute respiratory tract infection (ARI) from the perspective of a typical 
U.S. integrated delivery network (IDN) with a 1,000,000 member catchment area or 
enrollment. Methods: To conduct an economic evaluation of procalcitonin testing 
versus usual care we built a cost-impact model based on patient-level meta-analysis 
data of randomized trials. The meta-analytic data was adapted to the U.S. setting 
in reducing antibiotic exposure in adult ICU patients with sepsis, compared to cur-
rent practice in The Netherlands (NL), Germany and the UK. The reduction in anti-
biotic days as achieved by a PCT-algorithm is important given the rise in antibiotic 
resistance (ABR). Prolonged antibiotic duration affects the incidence of ABR and C. 
difficile infections (CDI), in this population amounting to 4.7% and 4.6% per hospital 
episode, respectively. We estimated the additional indirect cost savings of PCT-
testing by considering excess length of stay (LOS) due to ABR and CDI. Methods: 
Health economic consequences of a PCT-algorithm vs. current practice are analysed 
from a societal perspective using a decision tree. Input data were obtained from 
a systematic literature review and country-specific cost data sources. Effects of 
reduced duration of antibiotic therapy on ABR and CDI incidence and expected cost 
savings of a PCT-strategy were estimated for NL. Cost-effectiveness is expressed 
as incremental costs per antibiotic day avoided. Results: Excess LOS due to ABR 
and CDI is 4.6 days and 0.9 days per patient respectively. Shorter duration of anti-
biotic therapy, as achieved by a PCT-algorithm, decreases ABR and CDI incidence to 
4.5% and 3.9%, respectively. Including ABR and CDI costs in the analyses increases 
per-patient costs in both strategies, but less so for the PCT-algorithm. As a result, 
incremental cost savings of a PCT-algorithm compared to current practice increase 
with € 290 (from € 3,503 to € 3,793 per patient) when considering ABR and CDI. This 
further strengthens the dominance of the PCT-algorithm (ICER: -€ 2,231 per antibiotic 
day avoided). ConClusions: By reducing ABR and CDI incidence, a PCT-algorithm 
is expected to generate substantial indirect cost savings beyond direct health and 
economic impacts in ICU patients with sepsis.
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objeCtives: Consensus US cervical cancer screening guidelines recommend use of 
co-testing (combination Pap plus HPV testing) for women aged 30-65 years. Though 
not currently recommended by US guidelines, an HPV test was approved by the FDA 
in 2014 for primary cervical cancer screening in women 25 years and older. In this 
study, we perform clinical-economic comparisons of co-testing with genotyping 
(Co-test GT) versus primary HPV with genotyping and reflex cytology (HPV GT) for 
cervical cancer screening. Methods: A health state transition (Markov) model 
with one-year cycling was developed using epidemiologic, clinical, and economic 
data from healthcare databases and published literature. A cohort of one million 
women receiving triennial cervical cancer screening was simulated from ages 30-70 
years. Screening strategies compared HPV GT to Co-test GT. Outcomes included 
total and incremental differences in costs, invasive cervical cancer (ICC) cases, ICC 
deaths, and quality-adjusted life years (QALYs) for cost-effectiveness calculations. 
Comprehensive sensitivity analyses were performed. Results: In a simulation 
cohort of one-million 30-year-old women modeled up to age 70, the model predicted 
as many as 2,141 ICC cases and 2,040 ICC deaths could be prevented with Co-test GT 
versus HPV GT. Co-test GT demonstrated a greater number of lifetime QALYs (22,334) 
and yielded $36.1 million in savings compared with HPV GT, thereby conferring 
greater effectiveness at lower cost. Applying this model to the cross-section of 78.9 
million US women aged 30-70 years predicts nearly 150,000 ICC cases and more than 
100,000 ICC deaths could be avoided with Co-test GT versus HPV GT, representing 
cost savings of approximately $4 billion over 40 years. ConClusions: Model results 
demonstrate that co-testing with genotyping provides superior clinical and eco-
nomic outcomes when compared to primary HPV testing with genotyping and reflex 
cytology. These findings are important to US healthcare payers and women’s health 
policy advocates seeking cost-effective cervical cancer screening technologies.
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objeCtives: The aim of this study was to investigate the potential benefits and 
cost consequences of introducing 18F-Fluorodeoxyglucose Positron Emission 
Tomography (18F-FDG PET) in the diagnostic work-up of patients with suspected 
recurrent laryngeal cancer after radiotherapy. Methods: REcurrent LAryngeal car-
cinoma PET Study (RELAPS), a prospective multicenter randomized controlled trial, 
recruited 150 patients from eight head and neck cancer centers in the Netherlands 
and one center in Belgium. Two diagnostic algorithms were compared to the refer-
ence standard: (1) Conventional work-up (CWU); direct laryngoscopy with biopsy 
under general anesthesia, and (2)18F-FDG PET work-up (PWU) followed by laryn-
goscopy; only for positive or equivocal findings. Standard reference comprised his-
topathology and clinical follow-up of 6- and 12-months, respectively. Diagnostic 
performance of 18F-FDG PET and indication of unnecessary operations were effi-
cacy measures. Dutch healthcare perspective was used to obtain input parameters 
from hospital databases, patient records, literature and publicly available sources. 
Costs were expressed in 2014 Euros. Sensitivity analysis was performed. Results: 
Indication for direct laryngoscopy was classified unnecessary in 49 CWU patients 
(68%, 95%CI: 56-79) compared to 21 PWU patients (28%, 95%CI: 18-40) (p< 0.0001). 
The absolute difference between groups at 12-months was 40%. 18F-FDG PET had a 
sensitivity of 96% (95%CI, 78%-100%), specificity of 59% (95%CI, 44%-72%), a positive 
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remaining six program designs can all be considered cost effective depending on 
what the health-care decision makers are ready to pay for gaining a quality-adjusted 
life-year. ConClusions: Based on the results of the simulated screening programs, 
initiation of screening at the age of 75 with repeated screening at 80 years was found 
to be the most cost-effective design of a screening program for unknown AF when 
a QALY is considered to be worth approximately € 50,000.
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objeCtives: Accuracy standards of blood glucose monitoring systems have been 
recently revised. The revised standard, ISO 15197:2013, tightens the range of results 
considered accurate from a 20% deviation from the reference value to a 15%. The 
objective of this analysis is to evaluate the economic value of accuracy differences 
between ISO compliant and non ISO compliant meters in Spain, using a model-
ling approach. Methods: Clinical and economic outcomes were simulated over a 
20-years time horizon by means of a Markov model. 4 health states were considered, 
including no event, non-fatal hypoglycemia, fatal hypoglycemia and death due to 
other causes. Model inputs were derived from published sources. Inputs included 
Spanish Type 2 diabetes mellitus (T2DM) insulin-treated population size, risk of 
severe hypoglycemic event (SHE) due to meter error, cost per SHE and rates of death 
due to SHE and other causes. Results: A reduction of the inaccuracy range from 
20% to 15% would translate into a 25.5% reduction of SHE. The incremental cost per 
SHE avoided would be -2,795€ . The reduction in SHE would lead to cost savings of 
135€ per T2DM insulin-treated patient and year. Considering there are 379,728 T2DM 
insulin-treated patients in Spain, the total cost savings would exceed 51€ million, 
meaning 0.9% of total Spanish diabetes expenditure and 0.07% of total Spanish 
health care expenditure. ConClusions: Self-monitoring blood glucose is a key 
component of diabetes management as it is often used in clinical decision making. 
It is therefore critical that these devices are accurate and precise. The results of 
this study might encourage the conversion of all patients using non ISO compli-
ant meters to ISO compliant meters in the European Union, where ISO 15197:2013 
will become mandatory in May 2016. It might also enhance stricter standards in 
countries where these requirements will not be mandatory.
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objeCtives: Bladder cancer (BC) can be life-long and requires intensive and routine 
monitoring and treatment, which makes it costly and impacts on patients’ health 
perception. Hexaminolevulinate is a photosensitizing agent selectively absorbed by 
cancer cells which light up in red when illuminated with blue light, approved for 
improved detection and management of BC. The objective was to evaluate the cost-
consequences of using Hexaminolevulinate-guided blue-light flexible-cystoscopy 
(HBLFC) as an adjunctive to white-light flexible-cystoscopy (WLFC), compared with 
WLFC alone, in the detection of non-muscle invasive BC (NMIBC) one year after 
diagnosis and recurrence. Methods: A cost-consequence model using a combi-
nation of a decision tree and Markov cohort state transition model structure was 
developed using a Swedish setting, Swedish guidelines and a hospital perspective. 
231 patients were followed in an outpatient setting after diagnosed with NMIBC 
and successfully treated with an initial transurethral resection of bladder tumour 
(TURBT).The 231 patients were distributed across all risk groups. The model cap-
tured costs (2014 SEK) of surveillance and treatment of recurrence and progression 
over a 5-year period using 3-month-cycles. Results: The total cost over five years 
was marginally higher, 1.6%, for HBLFC (SEK 14,033,864) compared to WLFC (SEK 
13,815,155) although cost-saving from year 2. HBLFC resulted in reduced resource 
demand versus the comparator (TURBTs: 121.4 vs 126.1; cystectomies: 56.3 vs 58.8; 
operating room [OR] time [hours]: 428.9 vs 447.4; bed days: 18.7 vs 19.5). High-risk 
patients represented the largest share of the costs but also the main benefits in 
clinical outcomes. ConClusions: HBLFC was cost neutral over 5 years and reduced 
the number of bed days and OR time compared to WLFC alone, resulting mainly 
from fewer TURBTs and cystectomies. The greatest overall benefits were seen among 
high-risk patients, but other risk-groups are likely to benefit as well. Future model 
development will include quality-of-life data.
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objeCtives: The use of antibiotic-laden bone cements in surgical operations of 
the hip aims to help prevent surgical site infections (SSIs) and avoid their negative 
consequences. The objective of this study was to evaluate the costs and conse-
quences for the NHS in England and Wales associated with the use of a dual antibi-
otic cement (COPAL® G+C) compared to a single antibiotic cement (PALACOS® R+G) 
in the treatment of fractured neck of femur with hemiarthroplasty. Methods: A de 
novo decision tree model was developed, incorporating relevant clinical events of 
30-day mortality, superficial and deep SSIs, and revision procedures, over a 1 year 
time horizon. Probabilities were informed by published literature and results of a key 
randomised controlled trial comparing the two interventions. Costs were sourced 
by applying the meta-analytic results to U.S. lengths of stay, costs, and practice pat-
terns. We estimated the annual ARI visit rate for the one million member cohort, 
by setting (inpatient, ICU, outpatient) and ARI diagnosis. Results: In the inpatient 
setting, the costs of procalcitonin -guided care for the one million member cohort 
was $2,083,545, compared to $2,780,322, resulting in net savings of nearly $700,000 
to the IDN for the year 2014. The ICU and outpatient setting, the savings to the IDN 
were $73,326 and $5,329,824, respectively, summing up to overall net savings of 
$6,099,927 for the cohort. Results were robust for all ARI diagnoses. For the whole 
U.S. insured population, procalcitonin-guided care would result in $1.6 billion in 
savings annually. ConClusions: Our results show substantial savings associated 
with procalcitonin protocols of ARI across common U.S. treatment settings. These 
results are robust to changes in key parameters, and the savings can be achieved 
without any negative impact on treatment outcomes.
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objeCtives: The purpose of our analysis was to determine the costs of the con-
ventional three-dimensional radiation therapy (3DCRT) and the normal and hypo-
fractionated intensity-modulated radiation therapy (IMRT and HF-IMRT) for the 
treatment of localized prostate cancer, and to compare the treatment costs with 
the reimbursement fees. Methods: The cost-analysis was performed with micro-
costing method based on the data of a Hungarian oncology center from the per-
spective of the health care provider. We estimated the resource use in each phase 
of the radiation therapy process through face-to-face interviews with radiation 
oncologists, radiation therapists and physicists. The average positioning and treat-
ment delivery time were assessed from the data of 100 fractions delivered in 20 
patients. A unit cost for each cost component was calculated based on the actual 
costs retrieved from the accounting system of the oncology center. We assumed the 
irradiation scheme to use a total of 38 fractions in the 3DCRT and IMRT, and 25 frac-
tions in the hypofractionated scheme. Capital costs were taken into consideration in 
the cost calculation. Costs were converted to EUR by applying actual exchange rates 
(1 EUR = 309 HUF). Results: Based on our calculations the expected mean cost of 
patients undergoing 3DCRT, IMRT and HF-IMRT were 2,105 EUR, 3,066 EUR and 2,244 
EUR respectively. The current reimbursement fee for 38 and 25 fractions are 3,513 
EUR and 2,635 EUR respectively. ConClusions: Although IMRT and HF-IMRT has 
already been proven to be cost-effective compared to 3DCRT, the current reimburse-
ment fees do not encourage healthcare providers to use the more effective therapy 
techniques. The revision of intervention codes, DRGs and cost-weights in terms of 
radiation therapies for prostate cancer is desirable in order to resolve this anomaly.
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objeCtives: According to a number of publications frequency of complaints on 
temporomandibular joints (TMJ) ranges from 27 to 76% and is on a third place in 
modern dentistry after other dental diseases such as caries and its complications 
and periodontal pathology. The necessity of high-quality, relevant and available 
for patient diagnosis is increasing. To evaluate and compare the costs for diagnosis 
of patients with possible TMD from the payer’s perspective in the reform period of 
health care system and implementation of health insurance in Ukraine. Methods: 
For the diagnosis of TMJ violations such alternative methods may be used: ortho-
pantomography (OPG), zonography (ZG), ultrasonography (USG), 3D computed 
tomography (3D CT) and magnetic resonance imaging (MRI). From December 2013 
to June 2015 122 patients with suspected TMD at Prosthetic Dentistry Department 
Danylo Halytsky Lviv National Medical University were examined. Results: The 
above mentioned methods singly and in combination were used for diagnosis. The 
costs of examination according to the average data in private and public clinics in 
Lviv are: OPG - 5-7 € ; ZG - 5-7€ , USG - 7-9 € , 3D CT - 18-30 € , MRI - 30-50 € . Resulting 
62 OPG, 22 ZG, 54 USG, 20 3D CT and 2 MRI were conducted. Consequently, OPG, ZG 
and USG are available for most patients, less available is 3D CT. MRI is the most 
limited method. ConClusions: Such diagnostic methods as OPG, ZG and USG are 
the most available for patients. They are informative, have no excessive radiation 
exposure and allow them to re-apply if the forward observation is necessary. In 
some cases the 3D CT method should be combined with USG, so that complex has 
a higher cost. MRI is the “gold” standard for diagnosis, but the high cost and features 
of study may limit its usage.
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objeCtives: The primary objective of this study was to use computer simulations 
to determine the optimal age for initiation of screening for atrial fibrillation and 
to evaluate if repeated screening is of additional value. Methods: This analysis 
was based on a decision-analytic simulation model. More than one billion different 
designs of screening programs for unknown atrial fibrillation were simulated and 
analyzed. Widely accepted decision rules for mutually exclusive programs were used 
to identify optimal designs for screening for unknown atrial fibrillation. Results: 
Costs and effects generated by the 1,073,741,824 possible screening designs was 
calculated and compared. Of all possible programs, 1,073,741,818 designs were ruled 
out from the analysis based on dominance, extended dominance or the fact that 
the program design had an incremental cost of over € 100 000 per gained QALY. The 
